Eye disorders of origin, allergic.

Local channel.


According to the severity of the symptoms: 1 to 2, drops in the diseased eye, 2 to 4 times a day, at regular intervals.
After the improvement of the symptomatology, treatment should be pursued to maintain improvement.

If necessary, it is possible to associate treatment with ALMIDE eye drops in a single-dose container of corticosteroids.
Class: Pharmacotherapeutic: Other, antiallergic

(S '= organs, sensory)

ATC code S01GX05

In vitro, studies have demonstrated the ability of lodoxamide to stabilize mast cells and to inhibit the release of histamine specifically induced by the antigen. Lodoxamide prevents the release of other inflammatory mediators, such as the Slow Reacting Substance of Anaphylaxis, or SRS-A. It inhibits the release of histamine by opposing the penetration of calcium into mast cells after stimulation.

As with any eye drops, blurred vision, temporary vision or other visual disturbances may impair ability to drive or use machines. In the case of blurred vision occurring during instillation, the patient must wait until his vision returns to normal before driving a vehicle or using a machine
< Code>
Hypersensitivity to lodoxamide or to any of the components of eye drops

Do not inject, do not swallow.

Do not exceed the prescribed dosage.


Absence of study in children under 4 years

The data available to date do not imply the existence of clinically significant interactions.

Without object.

Local overdose is unlikely to be associated with toxicity. In case of local overdose, wash eyes with running water.
Accidental overdosage of an oral preparation of 120 to 180 mg of lodoxamide resulted in a transient heat sensation, abundant sweating, diarrhea, dizziness and stomach distension, no permanent adverse effects Has been observed

The doctor may resort to vomiting in case of accidental ingestion.


Studies carried out in animals have not been shown to have a teratogenic effect. In the absence of teratogenic effect in animals, a malformative effect in the human species is not expected. Indeed, to date, the substances responsible for malformations in the human species have been shown to be teratogenic in animals during studies, well conducted on two species
< Br>

There is currently no relevant or sufficient data to evaluate a possible malformative or foetotoxic effect of lodoxamide trometamol when administered during pregnancy. Therefore, as a precaution, it is preferable not to use lodoxamide trometamol during pregnancy.

Absence of data on the passage of lodoxamide in human milk

In clinical studies, the most frequently reported adverse reactions (in about 15% of patients) following eye drop instillation were: ocular irritation, transient (burning), eye pain (tingling) Or ocular discomfort

Nervous system disorders

Uncommon (> 1/1000 to ≤1 / 100): headache, dizziness, drowsiness
Eye disorders

Very common (≥1 / 10): eye irritation, pain, ocular discomfort, eye discomfort.
Frequent (> 1/100 to

Uncommon (> 1/1000 to ≤1 / 100): eye allergy, edema of the eyelids, vision disorder

Gastrointestinal disorders

Uncommon (> 1/1000 to ≤1 / 100), nausea, gastric disturbances
Skin and subcutaneous tissue disorders

Uncommon: (> 1/1000 to; ≤1 / 100): eruption.
Disorders, General and Site Anomalies, Administration

Uncommon (> 1/1000 to ≤1 / 100): sensation of heat.